A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.

• Status: Completed
• Trial end date: 2005-08-01
• Target enrollment: 0
• Participant gender: All

Summary

To demonstrate the efficacy and safety of aliskiren given to patients with both hypertension and diabetes mellitus

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Treatments: Ramipril

Criteria

Inclusion Criteria

• Patients with essential hypertension

• Patients with a documented diagnosis of Type 1 or Type 2 diabetes mellitus.

• Patients who are eligible and able to participate in the study

Exclusion Criteria

• Severe hypertension

• History or evidence of a secondary form of hypertension

• History of hypertensive encephalopathy or cerebrovascular accident. Other protocol-defined exclusion criteria may apply